BioMark Diagnostics Receives Clearance from Health Canada to Commence Clinical Trial with Patented Non-Invasive, Urine-Based Assay to Measure Response to Treatment for Lung Cancer

Sept 9thBioMark Diagnostics Receives Clearance from Health Canada (PDF)

 

———————————————

Share this post:
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2024 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.